3M Separation and Purification Sciences announces a global agreement with Thermo Fisher Scientific that lets biopharmaceutical customers more easily pair 3M Harvest RC Chromatographic Clarifier, a single-stage purification solution, with Thermo Scientific HyPerforma Single-Use Bioreactor Systems. This combination is designed to bring greater efficiency and scalability to the therapeutic manufacturing process.

To meet growing demand for protein-based therapeutics, manufacturers need advanced technologies and solutions that support reliable and consistent manufacturing processes. The collaboration between 3M and Thermo Fisher will enable manufacturers to capture high titer, high cell-density cultures to improve harvesting and clarification and optimize manufacturing capacity, quality and efficiency.

Released in June 2021, the 3M Harvest RC is 3M's newest solution that utilizes proprietary fibrous chromatography media to deliver a single-stage purification solution for recombinant protein therapeutic manufacturing. It is the latest innovation in harvest and clarification technology, streamlining a traditionally multi-stage harvest clarification process into a single stage. The technology supports a wide range of cultures with different cell densities, high-packed cell volumes, and cell culture characteristics, allowing manufacturers to achieve predictable performance, without programming every step.

"To have 3M Health Care and Thermo Fisher come together like this is an example of two leaders in science collaborating to drive forward next generation technology for biologics manufacturing," said Robert Befidi, president, 3M Separation and Purification Sciences. "The 3M Harvest RC in conjunction with Thermo Fisher's bioreactor systems brings forth a best-in-class solution to optimize manufacturing capacity to produce therapeutics." 

"Combining our highest-capacity bioreactor in the Thermo Scientific HyPerforma DynaDrive S.U.B. portfolio with the 3M Harvest RC Chromatographic Clarifier provides a best-in-class solution to our global biopharma customers," said Daniella Cramp, senior vice president and president of bioproduction at Thermo Fisher Scientific. "Integration of these technologies helps ensure efficient development of life-saving therapeutics for patients who need them."